Human Erythropoietin-alpha Recombinant

Recombinant human EPO-a is a glycosylated monomer protein consisting of 166 amino acids and, due to glycosylation migrates as an approximately 35 kDa protein under reducing conditions.

Product Specifications

Background

EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary endothelial and interstitial cells of the kidney. Approximately 10-15% of the total amount of Epo comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of Epo is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behavior of Epoin vivo. Non- glycosylated Epo has an extremely short biological half life. It still binds to its receptor and may even have a higher specific activityin vitro.

UniProt

P01588

Endotoxin

Endotoxin level was found to be < 0.1 ng/µg (1 EU/µg), using the LAL gel clot method.

Purity

≥ 98% by SDS-PAGE and HPLC

Format

Lyophilized protein

Reconstitution

A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/ml. This solution can then be diluted into other buffers.

Shipping Conditions

-20°C or-80°C

Storage Conditions

The lyophilized protein is stable for at least 2 years from date of receipt when stored at -20°C. Upon reconstitution, store in working aliquots at 2 - 8° C for up to one month, or at -20°C for up to six months, in the presence of a carrier protein. Avoid repeated freeze/thaw cycles.